DexCom, Inc. (DXCM)
70.70
-2.20
(-3.02%)
USD |
NASDAQ |
Mar 05, 16:00
70.70
0.00 (0.00%)
After-Hours: 20:00
DexCom Cash from Investing (Quarterly) : 306.60M for Dec. 31, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| BioLife Solutions, Inc. | 1.137M |
| Abbott Laboratories | -913.00M |
| Insulet Corp. | -152.80M |
| Krystal Biotech, Inc. | 11.16M |
| Boston Scientific Corp. | -512.00M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 294.00M |
| Cash from Financing (Quarterly) | -1.522B |
| Free Cash Flow | 1.077B |
| Free Cash Flow Per Share (Quarterly) | 0.4816 |
| Free Cash Flow to Equity (Quarterly) | 1.378B |
| Free Cash Flow to Firm (Quarterly) | 195.40M |
| Free Cash Flow Yield | 3.76% |